Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-07-31 02:01 UTC

BIOMED PULSE

Thursday, July 31, 2026 | Your daily briefing on longevity, viruses, and new cures

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in DRC and Uganda has now reached 2,124 confirmed cases and 828 deaths as of July 15 — the largest Ebola event in years, with cross-border spread still active. Mood: Urgent on the Ebola front; cautiously constructive on dementia prevention and food safety surveillance.

🦠 OUTBREAKS & VIRUSES

EBOLA (BUNDIBUGYO VIRUS) - DRC AND UGANDA

  • As of July 15, 2026, a cumulative 2,124 confirmed cases and 828 deaths from Bundibugyo virus disease (BVD) have been reported from the DRC, with cross-border transmission ongoing in Uganda. [1]
  • The PARTNERS clinical trial opened patient enrolment on July 2, 2026, inside DRC to identify the first effective treatments for Bundibugyo virus disease. [2]
  • WHO added the first molecular diagnostic test for Bundibugyo virus (BDBV) to its Emergency Use Listing on July 2, 2026, enabling rapid genetic confirmation from blood samples. [3]
  • WHO released its first comprehensive clinical management guidelines covering all Ebola and Marburg filovirus types in June 2026, timed directly to the DRC outbreak response. [4]
  • Africa CDC and WHO launched a joint continental Ebola preparedness and response plan in June 2026, seeking to raise US $518 million to support African countries. [5]

CYCLOSPORA - UNITED STATES

  • CDC confirmed shredded iceberg lettuce served at Taco Bell locations is the source of a Cyclospora outbreak infecting at least 1,644 people across five states as of July 17, 2026. [6]
  • The outbreak has since expanded to four additional states as of July 24, 2026; CDC is continuing its Cyclosporiasis response with updated transcripts as recently as July 14. [7][8]

ANDES HANTAVIRUS - M/V HONDIUS CRUISE SHIP

  • The fifth WHO Disease Outbreak News report (July 2, 2026) on the Andes hantavirus (ANDV) cluster linked to the M/V Hondius cruise ship confirms cases have spread to multiple countries following the initial notification on May 2, 2026. [9]
  • CDC provided ongoing hantavirus response updates through late June 2026, with the outbreak remaining an active international investigation. [10]

NIPAH VIRUS - INDIA

  • WHO confirmed one laboratory-confirmed Nipah virus (NiV) infection in Kozhikode district, Kerala State, India on June 11, 2026; the adult male presented with neurological symptoms and was hospitalized on June 10.
  • A separate NiV case was confirmed in Rajshahi Division, Bangladesh on February 3, 2026, with fever and neurological symptoms developing January 21; both cases represent the virus's continued seasonal emergence from its South Asian reservoir.

MPOX - RECOMBINANT STRAIN

  • WHO documented two cases of a recombinant monkeypox virus (MPXV) strain combining clade Ib and clade IIb genomic elements, reported in February 2026, raising concern about novel hybrid viral behavior.

WEST NILE VIRUS - UNITED STATES

  • CDC reported an early, record-breaking West Nile virus season as of July 1, 2026, urging mosquito bite prevention over the Independence Day holiday weekend.

YELLOW FEVER - GLOBAL

  • WHO reported that from January 1 to May 26, 2026, six countries across Africa and the Americas recorded 79 human yellow fever infections, following an uptick in the Americas in 2025 that carried into 2026.

E. COLI - FROZEN BLUEBERRIES

  • CDC issued a food safety alert on July 7, 2026, warning consumers not to eat recalled frozen blueberries linked to an active E. coli outbreak.

HIV - GLOBAL PROGRESS REPORT

  • WHO released a new report at AIDS 2026 (July 27) assessing Global Health Sector Strategy implementation, citing integration, innovation, and community leadership as keys to ending HIV, hepatitis, and STIs by 2030.

🧬 LONGEVITY & AGING

DEMENTIA PREVENTION - WHO GUIDELINES UPDATE

  • WHO released updated guidelines on July 15, 2026, concluding that up to 45% of dementia risk could be prevented or delayed through evidence-based interventions targeting modifiable risk factors across the life course.
  • The guidelines provide countries with actionable recommendations and represent the most significant update to WHO's dementia prevention framework in years.

NAD-PLUS RESTORATION FOR AGED BONE REPAIR

  • A new study in Bioactive Materials (June 27, 2026) describes a senescent metabolism-modulating hierarchical scaffold that restores NAD-plus homeostasis and redox balance to improve bone repair in aged tissue, targeting a core mechanism of cellular senescence.

KAEMPFEROL FROM MORINGA AND SENESCENCE

  • Research published in Toxicology Reports (June 25, 2026) found that kaempferol derived from Moringa oleifera increases longevity and reduces efavirenz-induced functional senescence in the Drosophila melanogaster model, linking a common flavonoid to lifespan extension and antiretroviral drug toxicity.

COLLAGEN XVII AND EPIDERMAL STEM CELL AGING

  • A study in Annals of Medicine (July 16, 2026) found that recombinant human collagen XVII protects epidermal stem cells from blue light-induced photoaging by downregulating the Notch signaling pathway, relevant to skin aging mechanisms.

TELOMERE REPAIR AND NUCLEAR AGING

  • Research published in Nucleus (July 23, 2026) examined repair and misrepair of telomeric DNA in dynamic interactions with PML nuclear bodies and lamin B1 in doxorubicin-treated cancer cells, illuminating how telomere maintenance intersects with nuclear aging processes.

TAU, EMERIN, AND NEURONAL CYTOSKELETAL REMODELING

  • A Nucleus journal study (July 7, 2026) linked elevation of the mechanically-sensitive nuclear envelope protein emerin to tau-induced cytoskeletal remodeling in neurons, connecting nuclear mechanotransduction to Alzheimer's-related pathology.

P16-INK4A SENESCENCE BIOMARKER VALIDATION

  • A methodological paper in Islets (July 21, 2026) highlighted the critical importance of antibody validation when detecting the senescence-associated cell-cycle regulator p16-INK4A by immunohistochemistry in pancreas tissue, cautioning against unreliable senescence measurements.

LYSOSOMAL AMPK ACTIVATION FOR FATTY LIVER DISEASE

  • A Bioactive Materials study (July 12, 2026) found that targeting ROAM1 with UDP-GlcNAc nanosheets selectively activates lysosomal AMPK to resolve metabolic dysfunction-associated steatotic liver disease (MASLD), offering a potential therapeutic avenue for an aging-linked liver condition.

💊 NEW CURES & APPROVALS

REZDIFFRA (RESMETIROM) - MADRIGAL PHARMACEUTICALS

  • Madrigal Pharmaceuticals received a supplemental approval (SUPPL AP) for Rezdiffra (resmetirom), a thyroid hormone receptor beta agonist originally approved for metabolic dysfunction-associated steatohepatitis (MASH); the supplement extends its regulatory profile.

SIMTRIYO (CENTANAFADINE) - OTSUKA PHARMACEUTICAL

  • Otsuka Pharmaceutical received an original approval (ORIG AP) for Simtriyo (centanafadine), a novel triple reuptake inhibitor of dopamine, norepinephrine, and serotonin, indicated for attention-deficit/hyperactivity disorder (ADHD).

LYTENAVA (BEVACIZUMAB-VIKG) - OUTLOOK THERAPEUTICS

  • Outlook Therapeutics received an original approval (ORIG AP) for Lytenava (bevacizumab-vikg), an anti-VEGF biologic indicated for wet age-related macular degeneration, a leading cause of vision loss in older adults.

XTANDI (ENZALUTAMIDE) - ASTELLAS

  • Astellas received two supplemental approvals for Xtandi (enzalutamide), an androgen receptor inhibitor used in prostate cancer, under NDA203415 and NDA213674, suggesting label expansion.

BREXAFEMME (IBREXAFUNGERP CITRATE) - GLAXOSMITHKLINE

  • GlaxoSmithKline received a supplemental approval for Brexafemme (ibrexafungerp citrate), a first-in-class triterpenoid antifungal for vulvovaginal candidiasis, expanding treatment options for fungal infections.

TYLENOL WITH NAPROXEN (NAPROXEN SODIUM PLUS ACETAMINOPHEN) - KENVUE

  • Kenvue Brands received an original approval (ORIG AP) for Tylenol with Naproxen, a fixed-dose combination OTC analgesic combining naproxen sodium and acetaminophen, NDA219962.

🧪 CLINICAL TRIALS

KARXT FOR ALZHEIMER'S DISEASE PSYCHOSIS (ADEPT-4) - NCT06585787

  • The ADEPT-4 Phase III trial is evaluating KarXT (xanomeline-trospium), a muscarinic cholinergic agonist, for safety and efficacy in adults with mild-to-severe Alzheimer's disease experiencing moderate-to-severe psychosis, representing a targeted non-dopaminergic approach to a major dementia complication.

PARTNERS TRIAL FOR BUNDIBUGYO VIRUS DISEASE - DRC

  • Patient enrolment opened July 2, 2026, in the PARTNERS international clinical trial in DRC to identify the first effective treatments for Bundibugyo virus disease, with WHO directly coordinating the effort. [2]

BAXDROSTAT FOR RESISTANT HYPERTENSION - NCT06034743

  • A Phase III multicentre, randomised, double-blind, placebo-controlled trial is evaluating baxdrostat 1 mg and 2 mg (an aldosterone synthase inhibitor) once daily versus placebo in approximately 720 participants with uncontrolled or resistant hypertension on two or more medications.

PSP CLINICAL TRIAL PLATFORM - NCT07173803

  • The Progressive Supranuclear Palsy (PSP) Clinical Trial Platform is a multi-center, multi-regimen adaptive trial evaluating safety and efficacy of multiple investigational agents for PSP, a rapidly fatal neurodegenerative disease with no approved treatments.

ISDHA HEALTHY AGING DATABASE - NCT07414680 - TAIWAN

  • A Phase IV observational study, Integrating Systematic Data of Medicine to Explore the Solution for Healthy Aging (ISDHA), is building a comprehensive geriatric health database for middle-aged and elderly people in Taiwan to inform future longevity interventions.

DIABETES PREVENTION PROGRAM OUTCOMES STUDY - NCT00038727

  • The long-running DPP Outcomes Study continues to follow participants originally enrolled in the multi-center trial testing intensive lifestyle intervention and metformin to prevent or delay type 2 diabetes in high-risk individuals with impaired glucose tolerance.

MIBG SCINTIGRAPHY FOR LEWY BODY DISEASE AND AGING - NCT05514106

  • A study using 123I-MIBG myocardial scintigraphy is investigating the radiotracer as a diagnostic tool to correlate cardiac nerve imaging with neurological aging disorders, including Lewy Body Disease.

📢 PUBLIC HEALTH

NEW CDC DIRECTOR SWORN IN

  • Susan Monarez, Ph.D., was sworn in today, July 31, 2026, as Director of the CDC by HHS Secretary Robert F. Kennedy Jr., to advance the Make America Healthy Again agenda.

WHO CANCER PROJECTION - URGENT ACTION CALLED

  • WHO reported on July 8, 2026, that new cancer cases are projected to nearly double by 2050, with current annual figures at 20.6 million new cases and close to 10 million deaths, or more than 26,000 deaths per day globally.

WHO DEMENTIA GUIDELINES - UP TO 45% PREVENTABLE

  • WHO's July 15 updated dementia guidelines identified modifiable risk factors whose reduction could prevent or delay up to 45% of dementia cases worldwide, a figure significantly higher than prior estimates.

GLOBAL CHILDHOOD IMMUNIZATION 2025

  • In 2025, 90% of infants globally (approximately 116 million) received at least one DTP vaccine dose, and 85% (110 million) completed the full three-dose series, according to WHO-UNICEF estimates released July 15, 2026, showing incremental but fragile progress.

DRUG-RESISTANT BACTERIA RISING - CDC REPORT

  • A CDC report released September 23, 2025, found a dramatic increase in a dangerous type of drug-resistant bacteria, reinforcing antimicrobial resistance as a critical and escalating public health threat.

CONGENITAL SYPHILIS - 12TH CONSECUTIVE YEAR OF INCREASE

  • CDC data released September 24, 2025, showed U.S. congenital syphilis cases increased for the 12th consecutive year in 2024, underscoring a persistent failure to interrupt vertical transmission.

LISTERIA - ONGOING PREPARED FOODS OUTBREAK

  • CDC expanded its Listeria outbreak alert to include additional prepared foods as of September 26, 2025, with 3 additional illnesses and 1 additional death reported; consumers are urged to check refrigerators and freezers for recalled products.

SALMONELLA - BACKYARD POULTRY

  • As of April 23, 2026, 34 people across 13 states are sick in a new Salmonella outbreak linked to backyard poultry; a May 14 update added 150 more cases, with over one quarter in children under age 5.

U.S. COMPLETES WHO WITHDRAWAL

  • The United States completed its formal withdrawal from the World Health Organization on January 22, 2026, citing COVID-19 response failures, politicization, and a shift to bilateral global health efforts.

This briefing is informational only and does not constitute medical advice. Always consult a licensed healthcare professional for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  2. Patient enrolment begins in a scientific trial to identify the… — WHO News
  3. WHO adds first diagnostic test for Ebola Bundibugyo virus to i… — WHO News
  4. WHO issues comprehensive guidelines on filovirus disease, incl… — WHO News
  5. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
  6. Shredded iceberg lettuce served at Taco Bell locations is sour… — CDC Newsroom
  7. Cyclospora outbreak linked to iceberg lettuce expanded to four… — CDC Newsroom
  8. Transcript - Update on CDC's Cyclosporiasis Response - 7/14/26 — CDC Newsroom
  9. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News
  10. Transcript - Update on CDC's Hantavirus Response - 6/24/26 — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260731-02-v44 · 2026-07-31 02:01 UTC · pulse.uzylab.com

Read next